Safety and utilization of Rivaroxaban in the secondary care setting in England
The overall aim of this Specialist Cohort Event Monitoring (SCEM) study is to proactively monitor the short-term (up to three months) safety and drug utilisation of rivaroxaban as prescribed to patients for medical conditions requiring anticoagulation by specialists in the secondary care setting in England. The study aims to collect exposure and outcome data for a cohort of approximately 2000 evaluable patients over a three year period.
- Adult (> 18 years?) patients prescribed rivaroxaban for all medical indications requiring anticoagulation (and surgical indications other than elective major hip or knee replacement).
- Patients who commenced rivaroxaban between date of market launch and study start - Initial survey questionnaire is not submitted within three months of the index date - Baseline and three month questionnaires are returned blank - Specialist reports that the patient did not take or was never prescribed rivaroxaban
Many locations, United Kingdom
E-mail: [email protected]
Phone: Not Available
An observational post-authorization safety specialist cohort event monitoring study (SCEM) to monitor the safety and utilization of Rivaroxaban (Xarelto®) in the secondary care setting in England